Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease.
It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Country | United States |
Founded | 1996 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | J. Finley |
Contact Details
Address: 7750 El Camino Real, Suite 2A Carlsbad, California 92009 United States | |
Phone | 858 704 4900 |
Website | palisadebio.com |
Stock Details
Ticker Symbol | PALI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001357459 |
CUSIP Number | 696389105 |
ISIN Number | US6963892046 |
Employer ID | 52-2007292 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
J. D. Finley | Chief Executive Officer, Chief Financial Officer and Director |
Dr. Mitchell Lawrence Jones M.D., Ph.D. | Chief Operating Officer and Chief Medical Officer |
Dr. Joerg Heyer Ph.D. | Head of Translational Science and Medicine |
Ryker Willie | Senior Vice President of Finance and Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | 10-K | Annual Report |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Dec 17, 2024 | 424B3 | Prospectus |
Dec 17, 2024 | 424B3 | Prospectus |
Dec 17, 2024 | 424B3 | Prospectus |
Dec 16, 2024 | EFFECT | Notice of Effectiveness |
Dec 16, 2024 | 8-K | Current Report |
Dec 13, 2024 | 424B5 | Filing |
Dec 13, 2024 | POS AM | Post-Effective amendments for registration statement |
Dec 12, 2024 | EFFECT | Notice of Effectiveness |